Athena Philis-Tsimikas, MD
- Endocrinology, Diabetes and Metabolism

Get directions
Hospital Affiliations
Languages
- Greek
- English
Biography
Athena Philis-Tsimikas, MD, is a specialist in endocrinology, diabetes and metabolism. She is the corporate vice president of the Scripps Whittier Diabetes Institute at Scripps Health and the director of community engagement for the Clinical Translational Science Award, housed at Scripps Research Translational Institute in San Diego.
With over 25 years of experience, she has served as a member of the Scripps Clinic Medical Group in the Division of Endocrinology and Diabetes and leads the diabetes care line for Scripps Health which creates programs, conducts research and delivers diabetes services across five Scripps hospitals, 25 outpatient facilities and the community.
Dr. Philis-Tsimikas is a leader of the innovative Project Dulce and Dulce Digital program which cares for under-resourced populations with diabetes. Dr. Philis-Tsimikas and Scripps Whittier Diabetes Institute are actively promoting participation of health centers in community-based clinical research with a focus on integrating digital technologies to improve diabetes care in the ambulatory and hospital setting. She is also Associate Clinical Professor of Medicine at UCSD’s Division of Endocrinology and Metabolism.
Dr. Philis-Tsimikas’ contributions to science include development of alternative, team-based care management programs for diverse patient populations; evaluation of telemedicine approaches to care and self-management education; creation and oversight of the Diabetes Medicines Clinical Trials program for Scripps Health; establishment of a systemwide glucose management program for a large community-based integrated health-care system; and assessment of health-care impact on costs in the diabetes population.
Dr. Philis-Tsimikas enjoys traveling, biking and harvesting olives to make extra virgin olive oil in Greece.
Board Certifications
Medical Education
Internships
Residencies
Fellowships
Publications
- Most Recent
- Alphabetical
- Oldest First
Quantifying Environmental Waste From Diabetes Devices in the U.S.
Tian T, Ho CN, Ayers AT, Aaron RE, Klonoff DC, Ahn DT, Kerr D, Peters AL, Philis-Tsimikas A, Shah VN, Herndon EG, Yang Y, Li C, Wang J
Copenhagen Declaration: a transformative vision for global diabetes.
Narayan KMV, Global Diabetes Forum (2024)
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, Pagliaro Rocha TM, Shankarappa VB, Terauchi Y, Ji L
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.
Philis-Tsimikas A, Bergenstal RM, Bailey TS, Jinnouchi H, Thrasher JR, Ilag L, Mitra J, Syring K, Threlkeld RJ
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.
DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators
Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.
Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
Kudva YC, Raghinaru D, Lum JW, Graham TE, Liljenquist D, Spanakis EK, Pasquel FJ, Ahmann A, Ahn DT, Aleppo G, Blevins T, Kruger D, Brown SA, Levy CJ, Weinstock RS, Steenkamp DW, Spaic T, Hirsch IB, Broyles F, Rickels MR, Tsoukas MA, Raskin P, Hatipoglu B, Desjardins D, Terry AN, Singh LG, Davis GM, Schmid C, Kravarusic J, Coyne K, Casaubon L, Espinosa V, Jones JK, Estrada K, Afreen S, Levister C, O'Malley G, Liu SL, Marks S, Peleckis AJ, Pasqua MR, Tardio V, Kurek C, Luker RD, Churchill J, Tajrishi FZ, Dean A, Dennis B, Fronczyk E, Perez J, Mukhashen S, Dhillon J, Ipek A, Bzdick S, Atakov Castillo A, Driscoll M, Averkiou X, Dalton-Bakes CV, Moore A, Jordan LF, Lesniak A, Pinsker JE, Sasson-Katchalski R, Campos T, Spanbauer C, Kanapka L, Kollman C, Beck RW, 2IQP Study Group
No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6.
Sourij H, Bracken RM, Carstensen L, Pagliaro Rocha TM, Kehlet Watt S, Philis-Tsimikas A
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.
Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators
-
Scripps Clinic John R. Anderson V Medical Pavilion
La Jolla, CA 920379898 Genesee Ave
Get directions
- Scripps Clinic Medical Group
If you see an error or omission on a provider’s profile page, please contact us.